International
The Morning Science

What science found today

‹
 

Research

Oligonucleotide-mediated AASS silencing as a potential therapeutic strategy for ALDH7A1 deficiency and glutaric aciduria type I

Science · By Reddy Sreekanth Vootukuri, Katarzyna Dyjach, Youssef Khalil, Joanna Toporowska, Sam Rowley, Charalambos Demetriou, Nicholas D. E. Greene, Kyle O’Sullivan, Barbara Plecko, Sidney M. Gospe, Alex Mackensie, Izabella A. Pena, Peter T. Clayton, Julien Baruteau, Paul Gissen, Haiyan Zhou & Philippa B. Mills ·

The Brief

  • A research article in Science Translational Medicine (November 2026) proposes silencing the AASS gene with oligonucleotides as a potential therapy.
  • The strategy is aimed at ALDH7A1 deficiency and glutaric aciduria type I.
  • The source is the article title and bibliographic details only; the study's results are not described in the provided material.

Why it matters

It proposes a gene-silencing approach for a rare inherited metabolic disorder, which could inform future therapy development for glutaric aciduria type I and ALDH7A1 deficiency.

Who’s affected

  • clinicians and researchers in inborn errors of metabolism
  • families and patients affected by glutaric aciduria type I
  • #glutaric aciduria type i
  • #aldh7a1 deficiency
  • #aass
  • #oligonucleotide therapy
  • #inborn errors of metabolism

Science Translational Medicine, Volume 18, Issue 876 , November 2026.

Timeline

  1. Article published in Science Translational Medicine

  2. science.org

    Oligonucleotide-mediated AASS silencing as a potential therapeutic strategy for ALDH7A1 deficiency and glutaric aciduria type I

How do you feel about this?

0 Comments

    Oligonucleotide-mediated AASS silencing as a potential therapeutic strategy for ALDH7A1 deficiency and glutaric aciduria type I – The Morning Science